MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2-breast cancer

被引：0
|
作者：
Rastogi, Priya
Toi, Masakazu
Harbeck, Nadia
Bourayou, Nawel
Frenzel, Martin
Johnston, Stephen
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Kyoto Univ, Grad Sch Med, Kyoto, Japan
[3] Univ Munich LMU, Breast Ctr, Munich, Germany
[4] Eli Lilly & Co, Paris, France
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-05-05
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2-Breast Cancer
    Bottosso, Michele
    Miglietta, Federica
    Vernaci, Grazia Maria
    Giarratano, Tommaso
    Dieci, Maria Vittoria
    Guarneri, Valentina
    Griguolo, Gaia
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2884 - 2894
  • [22] Adjuvant endocrine therapy combined with abemaciclib in monarchE patients with high-risk early breast cancer: Disease characteristics and endocrine therapy choice by menopausal status
    Paluch-Shimon, S.
    Lueck, H.
    Beith, J.
    Tokunaga, E.
    Contreras, J. Reyes
    de Sant'Ana, R. O.
    Forrester, T.
    McNaughton, R.
    Wei, J.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S427 - S428
  • [23] Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
    Tolaney, Sara M.
    Guarneri, Valentina
    Seo, Jae Hong
    Cruz, Josefina
    Abreu, Miguel Henriques
    Takahashi, Masato
    Barrios, Carlos
    McIntyre, Kristi
    Wei, Ran
    Munoz, Maria
    San Antonio, Belen
    Liepa, Astra M.
    Martin, Miguel
    Johnston, Stephen R. D.
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Harbeck, Nadia
    EUROPEAN JOURNAL OF CANCER, 2024, 199
  • [24] Long-term Patient-reported Outcomes from monarchE: Abemaciclib plus Endocrine Therapy for Adjuvant HR+, HER2-, Node-positive, High-risk, Early Breast Cancer
    Harbeck, Nadia
    Guarneri, Valentina
    Seo, Jae Hong
    Cruz, Josefina
    Abreu, Miguel Henriques
    Takahashi, Masato
    Barrios, Carlos
    Mcintyre, Kristi
    Wei, Ran
    Antonio, Belen San
    Liepa, Astra M.
    Martin, Miguel
    Johnston, Stephen R. D.
    Tolaney, Sara M.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 31 - 31
  • [25] A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+/HER2-early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)
    Hamilton, Erika
    Loibl, Sibylle
    Niikura, Naoki
    Rastogi, Priya
    Saini, Kamal S.
    Gioni, Ioanna
    Klinowska, Teresa
    Mayer, Ingrid A.
    Stuart, Mary
    Syta, Emilia
    Walding, Andrew
    Bachelot, Thomas
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Cost-effectiveness analysis of abemaciclib and endocrine therapy combination for the adjuvant treatment of HR+/HER2-, node-positive, high-risk, early breast cancer
    Talwar, Ashna
    Deshmukh, Ashish
    Trivedi, Meghana
    Aparasu, Rajender R.
    CANCER RESEARCH, 2023, 83 (07)
  • [27] Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR+/HER2-early breast cancer
    Slamon, Dennis J.
    Fasching, Peter A.
    Hurvitz, Sara
    Chia, Stephen
    Crown, John
    Martin, Miguel
    Barrios, Carlos H.
    Bardia, Aditya
    Im, Seock-Ah
    Yardley, Denise A.
    Untch, Michael
    Huang, Chiun-Sheng
    Stroyakovskiy, Daniil
    Xu, Binghe
    Moroose, Rebecca L.
    Loi, Sherene
    Visco, Frances
    Bee-Munteanu, Valerie
    Afenjar, Karen
    Fresco, Rodrigo
    Taran, Tetiana
    Chakravartty, Arunava
    Zarate, Juan Pablo
    Lteif, Agnes
    Hortobagyi, Gabriel N.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [28] Abemaciclib combined with endocrine therapy for the adjuvant treatment of high-risk early breast cancer
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Hegg, Roberto
    Toi, Mazakazu
    Martin, Miguel
    Shao, Zhimin
    Campone, Mario
    Hamilton, Erika
    Sohn, Joohyuk
    Guarneri, Valentina
    Cortes, Javier
    Neven, Patrick
    Boyle, Frances
    Smith, Ian C.
    Frenzel, Martin
    Headley, Desiree
    Wei, Ran
    Cox, Joanne
    O'Shaughnessy, Joyce
    Rastogi, Priya
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 112 - 113
  • [29] Patient-reported outcomes (PROs) of Chinese patients (pts) in monarchE: Abemaciclib plus endocrine therapy (ET) in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (EBC)
    Zhang, Q.
    Shen, K.
    Song, C.
    Ouyang, Q.
    Liu, Z.
    Liu, Q.
    Wang, X.
    Yang, Y.
    Qian, C.
    Shao, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1432 - S1432
  • [30] Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer
    Loi, Sherene
    Johnston, Stephen
    Arteaga, Carlos
    Graff, Stephanie
    Chandarlapaty, Sarat
    Goetz, Matthew
    Desmedt, Christine
    Reis-Filho, Jorge
    Sasano, Hironobu
    Rodrik-Outmezguine, Vanessa
    Sireci, Anthony
    Rubenstein, Cynthia Sandoval
    Won, Helen
    Liu, Deli
    Litchfield, Lacey M.
    Turner, Nicholas
    CANCER RESEARCH, 2024, 84 (09)
12345